Table 4.

Effect of training group, time point (TP), age, diabetes duration, ACE inhibitors, use of non-ACE inhibitors, statin use, and those study participants that commenced the study during the extended enrolment period on HbA1c.

HbA1c	β	SE β	Z statistic	P-value	Confidence interval
Training group	0.42	7.41	0.06	0.955	−14.11–14.95
TP1: Post 12 wk	−6.27	2.47	−2.54	0.011*	−11.11–−1.44
TP2: Post 6 mo	−3.60	2.54	−1.42	0.156	−8.59–1.38
Age	−0.42	0.43	−0.98	0.328	−1.26–0.42
T2D duration	0.05	0.54	0.10	0.923	−1.01–1.12
ACE	10.49	6.48	1.62	0.105	−2.21–23.19
Non-ACE	3.42	7.87	0.44	0.663	−12.00–18.84
Statins	0.06	5.75	0.01	0.992	−11.22–11.34
Extended	8.13	5.68	1.43	0.152	−3.01–19.26
Random-effects Parameters	Estimate	SE			Confidence interval
Subject: Identity Var (Cons)	134.68	42.32			72.76–249.33
Var (HbA1c)	33.48	7.12			22.07–50.79

Statistical significance is reported as follows:

^*P < 0.05.

ACE, angiotensin converting enzyme inhibitor; Cons, constant; HbA1c, glycated hemoglobin; mo, months; SE, standard error; TP, time point; T2D, type 2 diabetes mellitus; Var, Variable; wk, weeks.